The role of the proteasome in the generation of MHC class I ligands and immune responses - PubMed (original) (raw)
Review
The role of the proteasome in the generation of MHC class I ligands and immune responses
E J A M Sijts et al. Cell Mol Life Sci. 2011 May.
Abstract
The ubiquitin-proteasome system (UPS) degrades intracellular proteins into peptide fragments that can be presented by major histocompatibility complex (MHC) class I molecules. While the UPS is functional in all mammalian cells, its subunit composition differs depending on cell type and stimuli received. Thus, cells of the hematopoietic lineage and cells exposed to (pro)inflammatory cytokines express three proteasome immunosubunits, which form the catalytic centers of immunoproteasomes, and the proteasome activator PA28. Cortical thymic epithelial cells express a thymus-specific proteasome subunit that induces the assembly of thymoproteasomes. We here review new developments regarding the role of these different proteasome components in MHC class I antigen processing, T cell repertoire selection and CD8 T cell responses. We further discuss recently discovered functions of proteasomes in peptide splicing, lymphocyte survival and the regulation of cytokine production and inflammatory responses.
Similar articles
- PA28 and the proteasome immunosubunits play a central and independent role in the production of MHC class I-binding peptides in vivo.
de Graaf N, van Helden MJ, Textoris-Taube K, Chiba T, Topham DJ, Kloetzel PM, Zaiss DM, Sijts AJ. de Graaf N, et al. Eur J Immunol. 2011 Apr;41(4):926-35. doi: 10.1002/eji.201041040. Epub 2011 Mar 1. Eur J Immunol. 2011. PMID: 21360704 Free PMC article. - Proteasomes in immune cells: more than peptide producers?
Groettrup M, Kirk CJ, Basler M. Groettrup M, et al. Nat Rev Immunol. 2010 Jan;10(1):73-8. doi: 10.1038/nri2687. Epub 2009 Dec 11. Nat Rev Immunol. 2010. PMID: 20010787 Review. - Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex.
Vigneron N, Van den Eynde BJ. Vigneron N, et al. Biomolecules. 2014 Nov 18;4(4):994-1025. doi: 10.3390/biom4040994. Biomolecules. 2014. PMID: 25412285 Free PMC article. Review. - Thymoproteasome and peptidic self.
Takahama Y, Ohigashi I, Murata S, Tanaka K. Takahama Y, et al. Immunogenetics. 2019 Mar;71(3):217-221. doi: 10.1007/s00251-018-1081-3. Epub 2018 Oct 15. Immunogenetics. 2019. PMID: 30324237 Review. - Proteasome isoforms in human thymi and mouse models.
Mishto M, Takala I, Bonfanti P, Liepe J. Mishto M, et al. Immunol Lett. 2024 Oct;269:106899. doi: 10.1016/j.imlet.2024.106899. Epub 2024 Jul 15. Immunol Lett. 2024. PMID: 39019403 Review.
Cited by
- PSME2 offers value as a biomarker of M1 macrophage infiltration in pan-cancer and inhibits osteosarcoma malignant phenotypes.
Li R, Yan L, Jiu J, Liu H, Li D, Li X, Zhang J, Li S, Fan Z, Lv Z, Zhu Y, Wang B. Li R, et al. Int J Biol Sci. 2024 Feb 4;20(4):1452-1470. doi: 10.7150/ijbs.90226. eCollection 2024. Int J Biol Sci. 2024. PMID: 38385075 Free PMC article. - Fragmentation of SIV-gag vaccine induces broader T cell responses.
Benlahrech A, Meiser A, Herath S, Papagatsias T, Athanasopoulos T, Li F, Self S, Bachy V, Hervouet C, Logan K, Klavinskis L, Dickson G, Patterson S. Benlahrech A, et al. PLoS One. 2012;7(10):e48038. doi: 10.1371/journal.pone.0048038. Epub 2012 Oct 31. PLoS One. 2012. PMID: 23118924 Free PMC article. - In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.
Willimsky G, Beier C, Immisch L, Papafotiou G, Scheuplein V, Goede A, Holzhütter HG, Blankenstein T, Kloetzel PM. Willimsky G, et al. Elife. 2021 Apr 20;10:e62019. doi: 10.7554/eLife.62019. Elife. 2021. PMID: 33875134 Free PMC article. - Using gene expression to improve the power of genome-wide association analysis.
Ho YY, Baechler EC, Ortmann W, Behrens TW, Graham RR, Bhangale TR, Pan W. Ho YY, et al. Hum Hered. 2014;78(2):94-103. doi: 10.1159/000362837. Epub 2014 Jul 30. Hum Hered. 2014. PMID: 25096029 Free PMC article. - Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules.
Berkers CR, de Jong A, Schuurman KG, Linnemann C, Meiring HD, Janssen L, Neefjes JJ, Schumacher TN, Rodenko B, Ovaa H. Berkers CR, et al. J Immunol. 2015 Nov 1;195(9):4085-95. doi: 10.4049/jimmunol.1402455. Epub 2015 Sep 23. J Immunol. 2015. PMID: 26401003 Free PMC article.
References
- Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol. 1999;17:739–779. - PubMed
- Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995;41(4):178–228. - PubMed
- Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994;78(5):761–771. - PubMed
- Reits EA, Vos JC, Gromme M, Neefjes J. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature. 2000;404(6779):774–778. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous